Covid 19 Research using Clinical Trials (Home Page)
HP:0002098: Respiratory distressHPO
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (6)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug294 | Examine the impact of COVID-19 during pregnancy Wiki | 0.71 |
| drug763 | Standard Donor Plasma Wiki | 0.71 |
| drug680 | Rapid diagnostics using Anyplex TMII RV16 Detection Wiki | 0.71 |
| drug254 | Delayed diagnostics Anyplex TMII RV16 Detection Wiki | 0.71 |
| drug552 | Nitric Oxide Wiki | 0.50 |
| drug225 | Convalescent Plasma Wiki | 0.25 |
Correlated MeSH Terms (10)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004417 | Dyspnea NIH | 0.82 |
| D005335 | Fever of Unknown Origin NIH | 0.71 |
| D002637 | Chest Pain NIH | 0.71 |
| D011024 | Pneumonia, Viral NIH | 0.12 |
| D003141 | Communicable Diseases NIH | 0.08 |
| D014777 | Virus Diseases NIH | 0.08 |
| D011014 | Pneumonia NIH | 0.06 |
| D007239 | Infection NIH | 0.06 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
| D018352 | Coronavirus Infections NIH | 0.04 |
Correlated HPO Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100749 | Chest pain HPO | 0.71 |
| HP:0002090 | Pneumonia HPO | 0.11 |
There are 2 clinical trials
Clinical Trials
1 The Impact of Respiratory Pathogen PCR Assay on Treatment of Adult Patients: A Randomized Controlled Trial
Viral respiratory infections are common and often require use of health care resources. Patients receive inappropriate bacterial antibiotics, which has many problems including side-effects, development of resistance and costs. A small portion of the infections leads to severe clinical manifestations including hospitalisations and deaths. The significance of influenza virus is well known and it is actively detected in all age groups. However, the benefits of detecting other respiratory viruses have mainly been studied among children but not among adults. The development of multiplex PCR technique has provided a new and sensitive method for diagnosing a large panel of viruses. To convince the economical benefits of the rapid viral diagnostic in adult infectious patient, more evidence is needed. In our randomized study, nasal and pharyngeal samples from the patients evaluated at the emergency clinic of internal medicine in the University Hospital of Oulu because of any respiratory symptom, chest pain or fever, will be collected. The samples will be tested for 16 different respiratory viruses by using Anyplex TMII RV16 Detection. The adult participants will be randomized in two groups. In one group the results of the testing will be reported for the attending physician as soon as possible, and in the other group 7 days after sampling. The effect of this delay to patient care is monitored. Also the results of children and adults are compared as well as results of men and women. The hypothesis is that rapid viral diagnostics shortens the length of admission and diminishes the use of bacterial antibiotics. New information on the viral epidemiology among children and adults is provided and clinical manifestations of specific viral infections in adults are described. The estimated 1500 samples are also tested for 5 different respiratory bacteria by Anyplex TM II RB5 Detection. These results will be examined after completion of the study period. The benefits of rapid bacterial detection are evaluated in respect to the clinical course of the disease and considering the infection control aspects as well.
NCT02538770 Respiratory Virus Infection Fever of Unknown Origin Dyspnea Chest Pain Other: Rapid diagnostics using Anyplex TMII RV16 Detection Other: Delayed diagnostics Anyplex TMII RV16 Detection MeSH:Dyspnea Chest Pain Fever of Unknown Origin Virus Diseases
HPO:Chest pain Dyspnea Respiratory distress
Primary Outcomes
Description: The number of days in hospital within one month after randomization
Measure: Duration of hospitalization Time: One month
Description: Number of days on antimicrobials within one month after randomization
Measure: Antimicrobial consumption Time: One month
Description: Defined daily doses of antimicrobial agents within one month after randomization
Measure: Antimicrobial consumption Time: One month
Secondary Outcomes
Measure: Number of radiological examinations Time: One month
Measure: Cost of other examinations in hospital Time: One month
2 Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID19 Infection: a Randomized Clinical Trial
Primary Outcomes
Description: The number of days in hospital within one month after randomization
Measure: Duration of hospitalization Time: One monthDescription: Number of days on antimicrobials within one month after randomization
Measure: Antimicrobial consumption Time: One monthDescription: Defined daily doses of antimicrobial agents within one month after randomization
Measure: Antimicrobial consumption Time: One monthSecondary Outcomes
Measure: Number of radiological examinations Time: One monthMeasure: Cost of other examinations in hospital Time: One month
The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (COVID-19) originated in China in December 2019. At present, there are no proven interventions to prevent progression of the disease. Some preliminary data on SARS pneumonia suggest that inhaled Nitric Oxide (NO) could have beneficial effects on COVID-19 due to the genomic similarities between this two coronaviruses. In this study we will test whether inhaled NO therapy prevents progression in patients with mild to moderate COVID-19 disease.
NCT04290858 Coronavirus Infections Pneumonia, Viral Dyspnea Drug: Nitric Oxide MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia, Viral Pneumonia Dyspnea
HPO:Dyspnea Pneumonia Respiratory distress
Primary Outcomes
Description: The primary outcome will be the proportion of patients with mild COVID2019 who deteriorate to a severe form of the disease requiring intubation and mechanical ventilation. Patients with indication to intubation and mechanical ventilation but concomitant DNI (Do Not Intubate) or not intubated for any other reason external to the clinical judgment of the attending physician will be considered as meeting the criteria for the primary endpoint.
Measure: Reduction in the incidence of intubation and mechanical ventilation Time: 28 days
Secondary Outcomes
Description: Mortality from all causes
Measure: Mortality Time: 28 days
Description: Proportion of patients with a negative conversion of RT-PCR from an oropharyngeal or a nasopahryngeal swab
Measure: Negative conversion of COVID-19 RT-PCR from upper respiratory tract Time: 7 days
Description: Time from initiation of the study to discharge or to normalization of fever (defined as <36.6°C from axillary site, or < 37.2°C from oral site or < 37.8°C from rectal or tympanic site), respiratory rate (< 24 bpm while breathing room air) and alleviation of cough (defined as mild or absent in a patient reported scale of severe >>moderate>>mild>>absent).
Measure: Time to clinical recovery Time: 28 days
HPO Nodes
HP:0002098: Respiratory distress
Genes 230
DNAH9 DNAH11 ND5 EPHB4 SBDS TBC1D24 SPAG1 ORC1 TRNW ZFPM2 ND6 DNAAF3 GAS2L2 CCDC151 LYRM4 DISC1 CHRNE TRNV STT3B NDUFAF3 IFT81 CDT1 ETFA TRMU RSPH4A GBA TACO1 SLC52A3 NME8 COL2A1 COLQ FBP1 DNAAF4 ALDH7A1 MYO9A AGRN CCDC65 SLC18A3 TRNN FGFR2 ORC1 CFAP300 RUNX2 DNAI1 TRAK1 COX6B1 RSPH1 CCDC39 PMM2 ORC4 SLC2A10 DMPK DNAL1 MAPT ND2 ZMYND10 KAT6A NKX2-1 SURF1 COX8A MMAB SLC35A1 NUP214 GBA GAS8 CFAP298 DPM1 FGFR1 PUF60 IFT52 EP300 TRNE COX14 DNAAF2 MPC1 COL2A1 GMNN BMPER NDUFS2 ORC6 NAGS DNAAF1 PRSS1 PET100 SRP54 HLCS FAM20C COX20 EOMES CSF2RA RPS28 AIMP2 AIFM1 HCCS DNAAF6 STT3B DNAH5 SETBP1 PRRX1 SFTPC OTX2 SLC25A3 TTC25 LAMB2 SLC5A7 SPEF2 DNAAF5 TRIP11 LIFR TUBB4A NAGS ACADVL TK2 LGI4 ARMC4 COA8 SNAP25 ND3 RPS26 SERPING1 COL2A1 EFTUD2 ADCY6 KCNA1 FOXP3 CFAP221 IL1RN ND4 TRIP11 NGLY1 STAT5B MAPT COPA GATA6 MMAA MMUT ABCA3 SFTPB XYLT1 GATA6 VPS33A FOXJ1 CSF2RB MEGF10 SDCCAG8 ADAMTS13 ZIC3 CHAT FASTKD2 ETFB CCNO NDUFB8 CHAT STK36 FGFR2 TRNS1 KLHL7 POMT1 TRNE CNTNAP1 DNAH1 RSPH3 RSPH9 GNAI3 FBLN5 TRNL1 PRRX1 EDN1 DRC1 VAMP1 ADNP COX7B CPT2 CCDC103 ND1 DNAAF3 LRRC56 LRRC6 CCDC40 SLC25A1 SLC12A3 CFTR COQ7 SCO2 EDA SCO2 DMPK FOXF1 EFEMP2 PLCB4 UBE3B NKX2-1 OFD1 TRNK COL13A1 ITGA3 ETFDH COL2A1 DNAI2 SOX9 DNAJC21 SCO1 SYT2 USP9X DPM2 FGFR2 SSR4 USP9X COX10 CDC6 NDUFB11 CCDC114 FGFR2 DYNC2LI1 TRPV6 CDC45 DNAJB13 RPGR ATP6 CREBBP CLCNKB SIK1 CTRC DPM2 MMUT BMPER SPINK1 ERF MCIDAS HYDIN Protein Mutations 1
A118G SNP 1
rs7103572
Primary Outcomes
Description: The primary outcome will be the proportion of patients with mild COVID2019 who deteriorate to a severe form of the disease requiring intubation and mechanical ventilation. Patients with indication to intubation and mechanical ventilation but concomitant DNI (Do Not Intubate) or not intubated for any other reason external to the clinical judgment of the attending physician will be considered as meeting the criteria for the primary endpoint.
Measure: Reduction in the incidence of intubation and mechanical ventilation Time: 28 daysSecondary Outcomes
Description: Mortality from all causes
Measure: Mortality Time: 28 daysDescription: Proportion of patients with a negative conversion of RT-PCR from an oropharyngeal or a nasopahryngeal swab
Measure: Negative conversion of COVID-19 RT-PCR from upper respiratory tract Time: 7 daysDescription: Time from initiation of the study to discharge or to normalization of fever (defined as <36.6°C from axillary site, or < 37.2°C from oral site or < 37.8°C from rectal or tympanic site), respiratory rate (< 24 bpm while breathing room air) and alleviation of cough (defined as mild or absent in a patient reported scale of severe >>moderate>>mild>>absent).
Measure: Time to clinical recovery Time: 28 days